The Israeli fintech based out of Tel-Aviv and New York, Pagaya has announced that the company has raised $102 million in a Series D funding round. The fintech news space notes that this round was led by the Singapore Sovereign Wealth Fund (GIC). It also noted participation from Siam Commercial Bank, GF Investments, Clal Insurance Ltd., Harvey Golub, Oak HC/FT, Viola, Poalim Capital Markets, and Aflac Global Ventures.
The fintech firm was founded in 2015 and this fresh funding brings the total amount raised since the inception of the company to $146 million.
This global fintech firm makes use of artificial intelligence technology for reshaping the institutional investment as well as asset management areas. Pagaya was founded by CEO Gal Krubiner, CRO Yahav Yulzari, and CTO Avital Pardo, and the company now manages assets that are worth $2 billion in the United States. The fintech firm has offices in New York and Tel Aviv.
Krubiner stated that since the world is witnessing a shift in the paradigm quickly, investors are looking for a performance edge and so, more and more of them are turning to this fintech company. The company continues to unlock and provide unprecedented value with the utilization of its AI-driven solutions even during crisis-led situations and extremely stressful scenarios.
The company believes that being able to close a round of such great magnitude along with the support of a group that consists of such high-quality investors is a proof and testament of the far-stretched efforts and hard work of the team of the fintech firm.
To know more about such fintech news and information, keep following the fintecbuzz. Fintecbuzz provides its users with regular updates about the daily happenings in the fintech industry across the globe.
Aashish is currently a Content writer at FintecBuzz. He is an enthusiastic and avid writer. His key region of interests include covering different aspects of technology and mixing them up with layman ideologies to pan out an interesting take. His main area of interests range from medical journals to marketing arena.